Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain

Larrauri, Amparo; Cano, R.; García, Miriam; Mateo, Salvador de

doi:10.1016/j.vaccine.2005.03.045

Cited by 154 publications

(96 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…21 This is supported by data reported to ECDC, 1 according to which the proportion of SgC IMD among all serogrouped IMD cases in 2009 was 0% in Iceland, 0.5% in the UK, 5.1% in the Netherlands, 3.7% in Ireland, and 1.8% in Portugal, where catch-up campaigns targeted all persons up to 18 years or even older. In contrast, in Spain, where catch-up vaccination was limited to children 5 years and younger in 16/19 regions 22 and Belgium, 23 where catch up was limited to 1-6 year-olds in French regions and to 1-6 year olds and 15-18 year-olds in Flanders, the proportion of SgC IMD was higher at 7.1% and 13.8%, respectively, but still lower than in Germany (21.9%) or in countries that did not implement SgC vaccination before 2010, e.g. France (22.7%) or Denmark (32.8%).…”

Section: Discussionmentioning

confidence: 99%

Epidemiology of invasive meningococcal disease in Germany, 2002–2010, and impact of vaccination with meningococcal C conjugate vaccine

Hellenbrand

Elias

Wichmann

et al. 2013

Journal of Infection

View full text Add to dashboard Cite

SummaryObjectives: To analyse serogroup (Sg)-and finetype-specific invasive meningococcal disease burden (IMD) in Germany, 2002Germany, -2010, with emphasis on effects of vaccination with conjugate SgC vaccines targeting one-year old children since 2006, including individual-based catch-up to 17 years of age.Methods: Serogroup-and age-specific IMD incidence and trends were calculated using statutory surveillance data. The national reference laboratory performed genetic finetyping. Vaccination uptake data were obtained from school entry surveys and prescription monitoring. Results:In persons <25 years, SgB and SgC IMD incidence decreased significantly from 0.63 to 0.32/100,000 and 0.26 to 0.10/100,000, respectively. The decline was significantly steeper for SgC than SgB in 1-5 year-olds, the primary vaccination target group, but not other ages. The slope of the SgC incidence curves was similar before and after vaccination implementation in all age groups; however, the decrease in incidence was steeper in states with higher vaccination uptake. Declining SgC incidence was associated with decreased SgC finetype diversity. An increase in SgY incidence was limited to adults. Conclusions:Results suggest effects of the German SgC vaccination strategy are limited, although interpretation is complicated by already low and decreasing incidence before vaccination. More effective use of vaccination resources might be achieved by rigorously targeting adolescents in addition to 1-year-olds.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiology of invasive meningococcal disease in Germany, 2002–2010, and impact of vaccination with meningococcal C conjugate vaccine

Hellenbrand

Elias

Wichmann

et al. 2013

Journal of Infection

View full text Add to dashboard Cite

show abstract

“…[11][12][13][14] As also observed by Mooney et al 14 , the reversal of the increasing trend of serogroup C related IMD was simultaneous with the timing of MCC introduction and, therefore, likely attributable to it. The impact of MCC was investigated in many other European and Italian regional studies [14][15][16][17][18][19][20][21][22][23][24][25] which showed an important decrease in N. meningitidis C related IMD and a vaccine effectiveness as high as 100% depending on the age group and on the time elapsed from vaccination. A downward trend in serogroup C related IMD was also confirmed by the European Center for Disease Prevention and Control (ECDC) in countries with MCC vaccination.…”

Section: Discussionmentioning

confidence: 99%

Reduction inNeisseria meningitidisinfection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994–2012 series

Waure

Miglietta²,

Nedovic

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…It is interesting and unique that their introduction was initiated without any evidence of the vaccines' efficacy (it was extrapolated from polysaccharide vaccines), only with safety and immunogenicity confirmation (Miller et al, 2001). MCC vaccines apart from dramatic decrease of the incidence of MenC IMD in vaccinees, reduced also nasopharyngeal carriage, resulted in desirable herd immunity effect (Campbell et al, 2009;Larrauri et al, 2005;Miller et al, 2001). Consequently, the vaccine was successively introduced into national immunization programmes in some other European countries as well as in Australia, Canada and South America (Halperin et al, 2012;Jafri et al, 2013).…”

Section: St-11ccmentioning

confidence: 99%

Significance of Meningococcal Hyperinvasive Clonal Complexes and Their Influence on Vaccines Development

Waśko¹,

Hryniewicz²,

Skoczyńska³

2015

Pol J Microbiol

View full text Add to dashboard Cite

Neisseria meningitidis is a commensal of human nasopharynx and humans are the only known reservoir and host of this bacterium. It is also known as a dangerous and devastating pathogen, and infection with N. meningitidis may lead to rapidly progressing septicemia or meningitis. These severe infections, called invasive meningococcal disease (IMD), are one of the major public health threats worldwide. IMD may occur sporadically, but also in outbreaks, epidemics, and pandemics. Most of the IMD cases in the world are caused by isolates of genetically related groups, clonal complexes (CC), including those with special epidemiological significance called hyperinvasive clonal complexes. It is still unknown why some of them may persist for decades, whereas other are quickly replaced and disappear. As a consequence, the epidemiological situation of IMD is variable worldwide and greatly depends on the emergence and widespread of clones belonging to hyperinvasive clonal complexes. Their occurrence has serious implications for health policy, requiring often mass immunization campaigns. Paradoxically, alarming situations caused by hyperinvasive CCs stimulated the development and introduction of new vaccines against meningococci. Despite the unquestionable success of these vaccines, isolates of hyperinvasive clones constitute a permanent public health threat, because they are constantly circulating and able to modify their antigenic profiles to escape the host immune response. Therefore, continuous monitoring of meningococcal isolates including thorough molecular typing is indispensable and fundamental for taking appropriate preventive measures.

show abstract

Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain

Cited by 154 publications

References 7 publications

Epidemiology of invasive meningococcal disease in Germany, 2002–2010, and impact of vaccination with meningococcal C conjugate vaccine

Epidemiology of invasive meningococcal disease in Germany, 2002–2010, and impact of vaccination with meningococcal C conjugate vaccine

Reduction inNeisseria meningitidisinfection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994–2012 series

Significance of Meningococcal Hyperinvasive Clonal Complexes and Their Influence on Vaccines Development

Contact Info

Product

Resources

About